Signs of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.
Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.L44052,T862
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Levacetylmethadol. |
| Modafinil | The metabolism of Levacetylmethadol can be increased when combined with Modafinil. |
| Armodafinil | The metabolism of Levacetylmethadol can be increased when combined with Armodafinil. |
| Buprenorphine | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Hydrocodone | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Levacetylmethadol can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Levacetylmethadol may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Orphenadrine | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Pramipexole | Levacetylmethadol may increase the sedative activities of Pramipexole. |
| Ropinirole | Levacetylmethadol may increase the sedative activities of Ropinirole. |
| Rotigotine | Levacetylmethadol may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Levacetylmethadol. |
| Sodium oxybate | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Thalidomide | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Levacetylmethadol is combined with Desmopressin. |
| Naloxegol | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Naloxegol. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levacetylmethadol. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levacetylmethadol. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Levacetylmethadol. |
| Metreleptin | The metabolism of Levacetylmethadol can be increased when combined with Metreleptin. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Levacetylmethadol. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Levacetylmethadol. |
| Crizotinib | The metabolism of Levacetylmethadol can be decreased when combined with Crizotinib. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum toxin type B. |
| Mirtazapine | Levacetylmethadol may increase the serotonergic activities of Mirtazapine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Seproxetine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Alaproclate. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Fluvoxamine. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Zimelidine. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Sibutramine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Levacetylmethadol. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Indalpine. |
| Ethanol | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Levacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Levacetylmethadol. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Levacetylmethadol. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Levacetylmethadol. |
| MMDA | MMDA may increase the analgesic activities of Levacetylmethadol. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Levacetylmethadol. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levacetylmethadol. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levacetylmethadol. |
| Tenamfetamine | Tenamfetamine may increase the analgesic activities of Levacetylmethadol. |
| Chlorphentermine | Chlorphentermine may increase the analgesic activities of Levacetylmethadol. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may increase the analgesic activities of Levacetylmethadol. |
| Dextroamphetamine | Dextroamphetamine may increase the analgesic activities of Levacetylmethadol. |
| Metamfetamine | Metamfetamine may increase the analgesic activities of Levacetylmethadol. |
| Iofetamine I-123 | Iofetamine I-123 may increase the analgesic activities of Levacetylmethadol. |
| Ritobegron | Ritobegron may increase the analgesic activities of Levacetylmethadol. |
| Mephedrone | Mephedrone may increase the analgesic activities of Levacetylmethadol. |
| Methoxyphenamine | Methoxyphenamine may increase the analgesic activities of Levacetylmethadol. |
| Gepefrine | Gepefrine may increase the analgesic activities of Levacetylmethadol. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Levacetylmethadol. |
| Amphetamine | Amphetamine may increase the analgesic activities of Levacetylmethadol. |
| Phentermine | Phentermine may increase the analgesic activities of Levacetylmethadol. |
| Phendimetrazine | Phendimetrazine may increase the analgesic activities of Levacetylmethadol. |
| Naltrexone | The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Naltrexone. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Levacetylmethadol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Levacetylmethadol. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levacetylmethadol. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Diamorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Bezitramide. |
| Etorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Carfentanil. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Dihydromorphine. |
| DPDPE | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Lofentanil. |
| Normethadone | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Meptazinol. |